Clinical Evaluation of Fractional Radiofrequency for 
the Treatment and Reduction of Acne Scars and 
Wrinkles  
Protocol Identifying Number:  VI0919  
Principal Investigator:   [INVESTIGATOR_124]. Suzanne Kilmer  
Funded by : [CONTACT_484523]: [ADDRESS_674238]  
Toronto, ON  M2J 1R4  
Tel. 888 -907-0115  
Email: pcardarelli @venusconcept.com  
 
 
______________________________                      ___________________  
 Signature [CONTACT_484542] : (DD/MMM/YYYY)  
ii 
 Table of Contents  
STATEMENT OF COMPLIANCE  ............................................................................................................................. 1 
PROTOCOL SUMMARY  ........................................................................................................................................... 3 
SCHEMATIC OF STUDY DESIGN  .......................................................................................................................... 4 
1 KEY ROLES  .................................................................................................................................................... 4 
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENT IFIC RATIONALE  ........................ 5 
2.1 Background Information  ...................................................................................................................... 5 
2.2 Rationale  ............................................................................................................................................... 5 
2.3 Potential Risks and Benefits  .............................................................................................................. 6 
2.3.1  Known Potential Risks  ..................................................................................................... 6 
2.3.2  Known Potential Benefits  ................................................................................................ 6 
3 OBJECTIVES AND PURPOSE  .................................................................................................................... 6 
4 STUDY DESIGN AND ENDPOINTS  ........................................................................................................... 7 
4.1 Description of the Study Design  ........................................................................................................ 7 
4.2.1  Primary Endpoint  .............................................................................................................. 7 
4.2.2  Secondary Performance Endpoints  ............................................................................... 7 
4.2.3  Safety Endpoints  .............................................................................................................. 7 
5 STUDY ENROLLMENT AND WITHDRAWAL  ........................................................................................... 7 
5.1 STUDY POPULATION  ........................................................................................................................ 7 
5.2 Participan t Inclusion Criteria .............................................................................................................. 7 
5.3 Participant Exclusion Criteria ............................................................................................................. 7 
5.4 Strategies for Recruitment and Retention  ........................................................................................ 8 
5.5 Participant Withdrawal or termination  ............................................................................................... 8 
5.5.1  Reasons for Withdrawal or Termination  ....................................................................... 8 
5.5.2  Handling of Participant Withdrawals or termination  .................................................... 9 
5.6 Premature Termination or Suspension of Study  ............................................................................. 9 
6 INVESTIGATIONAL DEVICE  ..................................................................................................................... 10 
6.1 Investigational device and Control Description  ............................................................................. 10 
6.1.1  Acquisition  ....................................................................................................................... 10 
6.1.2  Device Specific Considerations  ................................................................................... 10 
6.2 Investigational device Accountability Procedures  ......................................................................... 11 
7 STUDY PROCEDURES AND SCHEDULE  .............................................................................................. 11 
7.1 Study Procedures/Evaluations  ......................................................................................................... 11 
7.1.1  Study specific procedures  ............................................................................................. 11 
7.2 Laboratory Procedures/Evaluations  ................................................................................................ 11 
7.2.1  Clinical Laboratory Evaluations  .................................................................................... 11 
7.2.2  Other Assays or Procedures  ........................................................................................ 11 
7.3 Study Schedule  .................................................................................................................................. 11 
7.3.1  Enrollment/Screening  .................................................................................................... 11 
7.3.2  Baseline Visit  .................................................................................................................. 12 
7.3.3  Treatment Visits  ............................................................................................................. 12 
7.3.4  Follow Up Visits  .............................................................................................................. 14 
7.3.5  Early Termination Visit  .................................................................................................. 14 
7.3.6  UNSCHEDULED Visit  ................................................................................................... 15 
7.3.7  Schedule of Events Table  ............................................................................................. 15 
7.4 Justification for Sensitive Procedures  ............................................................................................. 15 
iii 
 7.5 Concomitant Medications, Treatments, and Procedures  ............................................................. 15 
7.6 Prohibited Medications, Treatments, and Procedures  .................................................................  16 
7.7 Prophylactic Medications, Treatments, and Procedures  ............................................................. 16 
7.8 Rescue Medicatio ns, Treatments, and Procedures  ..................................................................... 16 
8 ASSESSMENT OF SAFETY  ...................................................................................................................... 16 
8.1 Specification of Safety Parameters  .................................................................................................  16 
8.1.1  Definition of Adverse Events (AE) and adverse device effect (ADE)  ..................... 16 
8.1.2  Definition of Serious Adverse Events (SAE)  .............................................................. [ADDRESS_674239] (SADE)  .................................................. 17 
8.1.4  Definition of Device deficiency  ..................................................................................... 17 
8.2 Classification of an Adverse Event  .................................................................................................  18 
8.2.1  Severity of Event  ............................................................................................................ 18 
8.2.2  Relationship to INVESTIGATIONAL DEVICE  ........................................................... 18 
8.2.3  Expectedness  ................................................................................................................. 19 
8.3 Time Period and Frequency for Event Assessment and Follow -Up .......................................... 19 
8.4 Reporting Procedures  ....................................................................................................................... 20 
8.4.1  Adverse Event Reporting  .............................................................................................. 20 
8.4.2  Serious Adverse Event Reporting  ............................................................................... 20 
8.4.4  Reporting of Pregnancy  ................................................................................................ 21 
8.5 Study Halting Rules  ........................................................................................................................... 21 
8.6 Safety Oversight  ................................................................................................................................ 21 
8.7 Training Requirements  ...................................................................................................................... 21 
9 CLINICAL MONITORING ............................................................................................................................ 21 
10.1  Statistical and Analytical Plans  ........................................................................................................ 22 
10.2  Statistical Hypotheses  ....................................................................................................................... 22 
10.3  Analysis Datasets  .............................................................................................................................. 22 
10.4  Descr iption of Statistical Methods  ................................................................................................... 23 
10.4.1  General Approach  .......................................................................................................... 23 
10.4.2  Analysis of the Primary Efficacy Endpoint(s)  ............................................................. 23 
10.4.3  Analysis of the Secondary Endpoint(s)  ....................................................................... 24 
10.4.4  Safety Analyses  .............................................................................................................. 24 
10.4.5  Adherence and Retention Analyses  ............................................................................ 25 
10.4.6  Baseline Descriptive Statistics  ..................................................................................... 26 
10.4.7  Planned Interim Analyses  ............................................................................................. 26 
10.4.9  Multiple Comparison/Multiplicity ................................................................................... 26 
10.4.10  Tabulation of Individual Response Data  ..................................................................... 26 
10.4.11  Exploratory Analyses  ..................................................................................................... 26 
10.5  Sample Size  ....................................................................................................................................... 26 
10.6  Measures to Minimize Bias  .............................................................................................................. 27 
10.6.1  Enrollment/ Randomization/ Masking Procedures  .................................................... 27 
10.6.2  Evaluation of Success of Blinding  ............................................................................... 27 
10.6.3  Breaking the Study Blind/Participant Code  ................................................................ 27 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  ................................... 28 
12 QUALITY ASSURANCE AND QUALITY CONTROL  .............................................................................. 28 
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  ................................................................................... [ADDRESS_674240]  .................................................................................................................................  29 
iv 
 13.2  Ethics committee and competent authorities  ................................................................................. 29 
13.3  Informed Consent Process  ............................................................................................................... 29 
13.3.1  Consent/assent and Other Informational Documents Provided to Participants .... [ADDRESS_674241] OF ABBREVIATIONS  ..................................................................................................................................... 34 
 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- [ADDRESS_674242] version of the Declaration of Helsinki 
(2013), ISO [ZIP_CODE] :2011  (Clinical investigation of medical devices for human subjects -  Good clinical 
practice ), Medical Devices Directive 93/42/EEC, MEDDEV 2.7/[ADDRESS_674243] of a clinical investigation of a medical device.  
The clinical investigation shall not begin until the required approval or favorable opi[INVESTIGATOR_10363] ( EC) has been obtained and, if applicable, any local or national regulatory authority approvals 
or notifications have been obtained.  
Any additional requirements imposed by [CONTACT_519799].  
The Sponsor has obtained clinical investigation insurance that will cover expenses in the event of any 
physical injury resulting from research procedures.  
  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  3 PROTOCOL SUMMARY  
 
TITLE  Clinical Evaluation of Fractional Radiofrequency for the Treatment and 
Reduction of Acne Scars and Wrinkles  
SUMMARY  Prospective,  single centre, evaluator -blind, split face study of the efficacy  of 
fractional radiofrequency (RF) for the treatment and reduction of acne scarring 
and facial wrinkles.  The study will evaluate the progress of [ADDRESS_674244] one 
treatment.  
OBJECTIVES  The objective of this clinical study is to evaluate the efficacy of fractional RF for 
the treatment and reduction of acne scarring or facial wrinkles.  
ENDPOINT  Primary performance endpoint s  
• Improvement  in acne  scarring  at [ADDRESS_674245] -treatment 
compared  to baseline  as assessed  by [CONTACT_519800]  (GAIS)  
• Improvement  in facial wrinkles  at [ADDRESS_674246] -
treatment  compared  to baseline  as assessed  by [CONTACT_519801]  (FWES)  
 
Secondary performance endpoints  
• Subjects’ assessment of satisfaction with the treatment using a Subject  
Satisfaction Scale at [ADDRESS_674247] -treat ment.  
 
Safety endpoints  
• Subject’s assessment of discomfort and pain after treatments as 
measured by a Wong -Baker FACES Pain Scale  and Tolerability Scale  
• Subjects experiencing a treatment- related adverse event ( AE) by [ADDRESS_674248] -Market  
NUMBER OF SITES  1  
DESCRIPTION OF 
DEVICE  The Venus Viva™ fractional RF device has been shown in clinical studies to 
improve various skin conditions related to aging and alter collagen structures such as wrinkles, rhytids  and scars .  The device offers the option of 80 and 160  
pin tips, to deliver nanofractional RF energy to the treatment site.  
STUDY DURATION  Approximately  8 months  
PARTICIPANT 
DURATION  6 months  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  4  
SCHEMATIC OF STUDY DESIGN  
 
Screening Visit  
 Screen Potential Subjects By [CONTACT_10385]; Obtain 
Informed Consent , Medical H istory, Physical Exam,  Demographics  
  
Visit 1–  
Baseline/Tx 1  
Day 0  Confirm Eligibility status, AEs, Concomitant Medication , Administer Study 
Treatment , Wong -Baker FACES Pain Scale and Tolerability Scale  
  
Visit 2 -Tx2 
Week 4  
(+/- 1 week)  AEs, Concomitant Medication , Administer Study Treatment, Wong -Baker FACES 
Pain Scale and Tolerability Scale  
  
Visit 3 -Tx3 
Week 8  
(+/- 1 week )  AEs, Concomitant Medication , Administer Study Treatment, Wong -Baker FACES 
Pain Scale and Tolerability Scale  
  
Visit 4 – FU1 
[ADDRESS_674249] - final 
treatment  
(+/- 1 week)  AEs, Concomitant Medication , Photographs, Subject  Satisfaction Scale, 
Treatment Evaluation Questionnaire  
  
Visit [ADDRESS_674250] -
final treatment  
(+/- 1 week)  AEs, Concomitant Medication, Photographs,  Subject  Satisfaction Scale, 
Treatment Evaluation Questionnaire  
  
[ADDRESS_674251]. Suzanne Kilmer  
Laser & Skin Surgery Center of Northern [LOCATION_004]  
[ADDRESS_674252]  
Sacramento, CA  
[PHONE_10811]  
 
  Paul Cardarelli  
Senior Director of Product Marketing and 
Clinical Affairs  
Venus Concept  
[ADDRESS_674253]  
Toronto, Ontario, M2J 1R4  
CANADA  
Tel. 888 -907-0115  
Email: [EMAIL_3066]  
 
 
  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  5  
2  INTRODUCTION: BACKGROUND INFORMATION AND SCIENTIFIC RATIONALE  
 
2.[ADDRESS_674254] -acne sequelae2.  
Current  procedures such as chemical or laser peels, dermabrasion or non ablative laser resurfacing are 
usually associated with prolonged recovery times as well as arduous side effects1. To circumvent thes e 
issues, the use of non -invasive, nonsurgical approaches that do not require downtime are becoming the 
preferred method of choice for patients seeking  cosmetic improvements.  An innovative technique that 
was introduced to reduce facial wrinkles and rhytid es is known as radiofrequency (RF).  
Treatment of acne scars with fractional RF therapy has been shown to promote remodeling of the 
dermis to replace acne  scar-associated irregularities  with a  more normal architecture, particularly in the 
case of elastic fibers and  over -deposition of elastin6. 
The premise behind RF technology is dermal heating,  which initiates the denaturation of collagen and 
the stimulation of neocollagenesis through the  induction of inflammation that leads to the production of 
fibroblasts at the heated area and the  subsequent development of new collagen.2 RF energy produces 
an oscillating electrical current that can penetrate the dermis and hypodermal tissues without disturbing 
the epi[INVESTIGATOR_3915] -dermal barrier. The generation of the  heat energy is the result of the natural resistance 
that dermal tissue has to the movement of ions with an electromagnetic field. Accordingly, the oscillating electrical current causes collisions between charged ions that are transformed into heat energy.
2 The production of heat energy through RF typi[INVESTIGATOR_484514], coagulation, and skin 
resurfacing.    
Mono -polar RF devices were used initially for facial treatments, and although the results appeared to be 
promising, this approach was associated with serious pain as well as the high incidence of adverse events including second -degree burns that are caused by [CONTACT_484526].
5 Bipolar and multi- polar RF devices allow the heat energy to be distributed m ore evenly 
with less depth -penetration, thereby [CONTACT_519802] a patient’s skin type.    
Therefore, RF techniques that improve the ability to control the ablation and coagulation of the skin can 
result in treatment consistency that will provide more flexibility to treat a wider variety of skin conditions.   
2.2 RATIONALE  
Fractional RF techn ology has been shown in clinical studies to improve skin laxity, and to treat various 
skin conditions related to aging and alternate collagen structures such as wrinkles, rhytids  and scars .   
The objective of this clinical study is to evaluate the safety and performance of fractional RF for the 
treatment of acne scarring  and wrinkles.  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  6 The use of the Venus Viva ™ has been determined to present non -significant risk in accordance with 21 
CFR 812.3 for the intended use in this study, because the device is not:  
• Intended as an implant;  
• Purported or represented to be for use supporting or sustaining human life;  
• Substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise 
preventing impairment of human health  
• Otherwise present ing a potential for serious risk to the health, safety, or welfare of a subject.  
This study will be conducted in compliance with the protocol and according to Go od Clinical Practice 
(GCP) standards.  
2.[ADDRESS_674255] -treatment, e xcessive skin redness (erythema) and/or swelling 
(edema) , in-grown hairs , damage to natural skin texture (crust, blister, burn) , change of pi[INVESTIGATOR_371] 
(hyper - and hypo -pi[INVESTIGATOR_371])  and scarring . Treatment of hair- bearing areas in male patients may 
result in some damage to the  follicles and subsequent loss of hair.  Avoid the beard area and other hair-  
growing zones if the patient does not wish to experience hair growth reduction.   
Further information about residual risks associated with the device  and with participation  in the  clinical 
investigation are reported in the device User Manual . 
Residual risks will be mitigated as follows:  
− Selection of an investigator with experience in the therapeutic area of the clinical investigation  
− Investigator and site staff will have already undergo ne training prior to patients’ enrollment  
− Prior to  the first procedure, the investigator and site staff will undergo a re -training session by 
[CONTACT_484528]  
− Patients will be rigorously screened prior to their enrollment  
− Patients will be rigorously followed over the course of the study  
 
2.3.[ADDRESS_674256] agrees to participate in this study, he/ she will be contributing to the understanding of the 
device’s impact and the biol ogical processes that are occurring regarding  acne scar  and wrinkle  
formation . This understanding may lead to optimization of the treatment with this device  for these 
indications .  In addition,  the subject may benefit from improvement in acne scar  and wrinkle  
appearance in the treated area s. 
3 OBJECTIVES AND  PURPOSE  
This clinical study is being conducted  to evaluate the efficacy  of nano fractional RF for the treatment and 
reduction of acne scarring  and wrinkles . Total expected duration of the clinical investigation  is eight 
months  (enrolment period of 2 months, follow -up period of 6  months ), while individual subject 
participation will take  approximately  6 months.   
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  7  
4 STUDY DESIGN AND ENDPOINTS  
 
4.1 DESCRIPTION OF THE STUDY DESIGN  
This is a p rospective, single centre, evaluator- blind, split face study of the efficacy of fractional 
radiofrequency (RF) for the treatment and reduction of acne scarring and facial wrinkles.  
4.2.1 PRIMARY ENDPOINT  
 
• Improvement  in acne  scarring  at [ADDRESS_674257] -treatment compared  to baseline  
as assessed  by [CONTACT_519803]  (GAIS)  
• Improvement in facial wrinkles  at [ADDRESS_674258]- treatment  compared to baseline 
as assessed by [CONTACT_519804] (FWES)  
4.2.2 SECONDARY PERFORMANCE ENDPOINTS  
• Subj ects’ assessment of satisfaction with the treatment using a Subject Satisfaction 
Questionnaire  at [ADDRESS_674259]- treatment.  
4.2.3  SAFETY ENDPOINTS  
•  Subject’s assessment of discomfort and pain after treatments as measured by a Wong- Baker 
FACES P ain Scale  and Tolerability Scale  
• Subjects experiencing a treatment- related adverse event ( AE) by [ADDRESS_674260] -treatment.  
5 STUDY ENROLLMENT AND WITHDRAWAL  
 
5.1 STUDY POPULATION  
The study will enroll 15  male or female adult subjects requesting fractional radiofrequency treatment of 
acne scarring or wrinkles according to study protocol .   
5.2 PARTICIPANT  INCLUSION CRITERIA  
1. Healthy , male or female subjects over 21 years of age  who are seeking treatment and reduction 
of their acne scarring  or wrinkles . 
2. Able to read, understand and voluntarily provide written Informed Consent . 
3. Able and willing to comply with the treatment/follow -up schedule and requirements . 
4. Women of child -bearing age are required to be using a reliable method of birth control at least [ADDRESS_674261] at baseline.  
5.3 PARTICIPANT  EXCLUSION CRITERIA  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  8 1. Pacemaker o r internal defibrillator, or any other active electrical implant anywhere in the body 
(e.g. cochlear implant).  
2. Subjects with any implantable metal device in the treatment area  
3. Permanent implant in the treated area, such as metal plates and screws  (excludin g dental 
implants) , or an injected chemical substance.  
4. Current or history of any kind of cancer, or dysplastic nevi  
5. Severe concurrent conditions, such as cardiac disorders.  
6. Pregnancy or intending to become pregnant during the study and nursing.  
7. Impaired immune system due to immunosuppressive diseases, such as AIDS and HIV, or use of 
immunosuppressive  medications.  
8. History of diseases stimulated by [CONTACT_10388], such as recurrent herpes simplex in the treatment area ; 
may be enrolled only following a prophylactic regime.  
9. Poorly controlled endocrine disorders, such as diabetes.  
10. Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.  
11. History of skin disorders, such as keloids, abnormal wound healing, as well as very dry an d 
fragile skin.  
12. History of bleeding coagulopathies, or use of anticoagulants  (excluding daily aspi[INVESTIGATOR_248]) . 
13. Facial dermabrasion, facial resurfacing, or deep chemical peeling within the last three months, if face is treated.  
14. Use of isotretinoin (Accutane®) or o ther systemic retinoids within six months prior to treatment 
or as per investigators discretion.  
15. Any surgical procedure in the treatment area within the last six months or before complete healing.  
16. Treating over tattoo or permanent makeup.  
17. Excessively tann ed skin from sun, tanning beds or tanning creams within the last two weeks.  
5.[ADDRESS_674262] been treated according to the 
study protocol .  It is anticipated that it will take up to eight months  to complete the study.  Subjects  will  
primarily be recruited from the investigator’s practice .  Any advertising campaigns and materials will be 
reviewed and approved by [CONTACT_10389] I nstitutional Review Board ( EC or IRB) before 
implementation.  Due to the long duration of the study, subjects will be contact[CONTACT_10390] a regular basis to  enhance retention.  
5.[ADDRESS_674263] drops out of the study or is withdrawn from the study, the E nd of 
Study /Early Discontinuation  CRF form should be completed.  On the discontinuation  page , the 
Investigator should record the date of the withdrawal and the reason for withdrawal.   
Reasonable effort should be made to contact [CONTACT_519805].  The records of subjects who 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  9 terminate prior to completing the study will be retained and the reason for termination will be 
documented.  
The investigator may terminate participation in the study if:  
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs such that continued participation in the study would not be in the best interest of the subject.  
• The subject  meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation.  
5.5.[ADDRESS_674264] an exit visit  (final study visit, see 
section 7.3.5)  to withdrawn patients , and to  undertake protocol -specified safety follow -up procedures 
to capture AEs, serious adverse events (SAEs) an d device deficiencies.   
5.6 PREMATURE TERMINATION OR SUSPENSION OF STUDY  
The sponsor may suspend or prematurely terminate this study at  the investigation site fo r significant and 
documented reasons.  
 A principal investigator, EC/IRB, or regulatory authority may suspend or prematurely terminate 
participation in the study at the investigation site for which they are responsible.  
 
If suspi[INVESTIGATOR_519793], or when so instructed by [CONTACT_1383]/IRB 
or regulatory authorities, the sponsor shall suspend the clinical investigation while the risk is assessed.  
The sponsor shall terminate the study if an unacceptable risk is confirme d. 
 
The sponsor shall consider terminating or suspending the participation of the investigation site or 
investigator in the study if monitoring or auditing identifies serious or repeated deviations on the part of an investigator.  
 If suspension or premature termination occurs, the terminating party shall justify its decision in writing  
and promptly inform the other parties with whom they are in direct communication. The principal 
investigator [INVESTIGATOR_519794]/IRB or the regulatory authority.  
 
If, for any reason, the sponsor suspends or prematurely terminates the study at the investigation site, the 
sponsor shall inform the responsible regulatory authority as appropriate and ensure that the EC/IRB is notified, either by [CONTACT_458] [INVESTIGATOR_10368].   If the suspension or premature termination 
was in the interest of safety, the sponsor shall inform all other principal investigators.  
 
If suspension or premature termination occurs,  
a) the sponsor shall remain responsible for providing resources to fulfil t he obligations from the 
clinical investigative plan  and existing agreements for following up the subjects enrolled in the 
study, and  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  10 b) the principal investigator [INVESTIGATOR_484516], if appropriate  
 In case of early termination, final study activities according to the protocol, including the follow up visits 
and proc edures to assess the safety and efficacy of the device will be conducted, regardless of the 
sponsor's interest in the study.  Follow -up activities will be conducted so that device deficiencies can be 
identified and appr opriate safety measures can be implem ented.  
 
At the completion or termination of the study, the Investigator will return all remaining clinical supplies 
to Sponsor along with a copy of the device supply and inventory records.  
 
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  (examples of 
findings that might trigger a safety review are the number of SAEs overall, the number of 
occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of events  – 
refer to sec tion 8.5 STUDY HALTING RULES . 
• Demonstration of performance  that would warrant stoppi[INVESTIGATOR_007] 
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination of futility  
Study may resume once concerns about safety, protocol compliance, data quality are addressed and 
satisfy the sponsor, EC / IRB and/or regulatory authorities . 
6 INVESTIGATIONAL DEVICE  
 
6.1 INVESTIGATIONAL DEVICE  AND CONTROL DESCRIPTION  
 
6.1.1  ACQUISITION   
If the investigative  site does not own a Venus Viva™,  a device  will be provided  by [CONTACT_456].  An 
activation code will be required to activate the device  (not applicable if the site owns the device) .  This 
code  will be pro vided to the investigative site once  all regulatory and EC/IRB approvals are in place and 
the site has received training for both the device and the study  (if applicable) .  
6.1. 2 DEVICE SPECIFIC CONSIDERATIONS  
• Device model(s)  - Venus Viva ™  
• Device settings and programming –  Ablation and Coagulation  Mode ; 180-280 volts, 5-30 ms 
pulse duration  
• Duration of exposure and frequency –   
o For all subjects – single or multiple pass , monthly for 3 months .   
The Venus Viva ™ is a non -invasive medical aesthetic device, intended for use in dermatologic and 
general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.    
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  11 The system consists of a handheld applicator  with disposable tips.  The tip options  include an 80 and 160 
pin  tips, 8x20 mm in size , that delivers the Multi Polar Radiofrequency (RF)  to the skin .  Further  details 
about t he Venus Viva ™ can be found  in the  device User Manual.  
6.2 INVESTIGATIONAL DEVICE  ACCOUNTABILITY PROCEDURES  
If the device is supplied by [CONTACT_456], t raceability shall be achieved during and after the clin ical 
investigation by [CONTACT_10392].   Disposal tips will be provided 
by [CONTACT_456].  
7 STUDY PROCEDURES AND SCHEDULE  
 
7.1 STUDY PROCEDURES/EVALUATIONS  
7.1.1  STUDY SPECIFIC PROCEDURES   
The following procedures and evaluations will be done as part of the study : 
Demographics  
Medical /surgical history (obtained by [CONTACT_10393]/ or medical records)  
Physical examination  
Assessment of eligibility  
Photographs   
Blinded assessment  
Administration of questionnaires and scales for blinded reviewer and patient -reported outcomes  
Adverse event recording 
Concomitant medications  
7.2 LABORATORY PROCEDURES/EVALUATIONS    
 
7.2.[ADDRESS_674265] to be performed within 24 hours of study intervention with results available prior 
to administration of treatment.     
7.2.2  OTHER ASSAYS OR PROCEDURES  
None.   
7.3 STUDY SCHEDULE  
 
7.3.1  ENROLLMENT/ SCREENING  
 
Screening and Enrolment  Visit (Day -7 to 0 ) 
 If the subject meets the preliminary study criteria , the study doctor, and/or his /her  designee, will obtain 
an informed consent from the subject  prior to any study procedure , clearly indicating his/her 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- [ADDRESS_674266]'s case report form (CRF).  
During the first visit, the study investigator, and/or his /her  designee, will screen the subject for eligibility 
to participate in the clinical study using the i nclusion /exclus ion criteria.  A negative urine pregnancy test 
will be obtained  (in patients of child -bearing potential) .  During screening, the study doctor will review 
the subject's medical /surgical history , demographics, conduct a physical exam  and examine the subject' s 
targeted treatment area to ensure that it meets the study criteria.  The subject will complete screening 
and the treatment will be scheduled.  
7.3.2  BASELINE  VISIT  
Baseline  Visit (Visit 1  – Day 0 ) 
Subjects will return to the clinic roughly [ADDRESS_674267] of 
three treatments  (see 7.3.3) .  Adverse events  and any changes to concomitant medications will be 
recorded. Photographs of the treatment area will be t aken.  
 
7.3.3  TREATMENT VISITS  
Beginning with the Baseline visit (Visit 1 ), subjects will receive a total of 3 treatments approximately 3-5 
weeks apart .  Adverse events and any changes to concomitant medications will be recorded  at these 
visits . 
Subjects will receive treatment as described below.   Following treatment, the investigator will examine 
the treated area and report immediate and short term response.  Subjects will complete the Wong-
Baker FACES Pain Scale and Tolerabilit y Scale immediately after treatment.   Photographs will also be 
taken at each of these study visits.  
The investigator will examine the treated areas and report immediate and short term response ([ADDRESS_674268] -treatment) (pain during treatment, hemorrhage,  burn, erythema, edema, purpura) using a 
5-point scale: 1=none; 2=trace; 3=moderate; 4=marked; 5=severe.    
The normal response to these treatments is transient erythema and edema. If any other side effects occur, as indicated in the protocol, they must be recorded.  
Visit 1 – Day [ADDRESS_674269] of the three treatments , treatment parameters will be selected by 
[CONTACT_093].   In addition to the treatment, concomitant medications, photographs and the Wong -
Baker FACES Pain Scale and Tolerability Scale are to be completed by [CONTACT_102].  
Visit 2 – Week 4 (+/- 7 days)  
The Subject is to return to the clinic for their second of the  three treatments.  In addition to the 
treatment, concomitant medications, photographs, AEs and Wong -Baker FACES Pain Scale and 
Tolerability Scale are to be completed by [CONTACT_102].  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  13 Visit 3 -- Week 8 (+/- 7 days)  
The Subject is to return to the clinic for  their final treatment.  In addition to the treatment, concomitant 
medications, photographs, AEs and Wong -Baker FACES Pain Scale and Tolerability Scale are to be 
completed by [CONTACT_102].  
 
Treatment  
Shave any hair in the treatment area.  Ensure that the skin is completely dry during the entire treatment. 
If the skin moistens during treatment (i.e. perspi[INVESTIGATOR_1516], etc.) re -wipe the skin with an alcohol pad and 
ensure that the skin is completely dry before continuing the treatment.  
Set the treatment parameter s to desired treatment mode and select the appropriate tip (160 pin or 80 
pin tip) .  Set the desired energy level according to the skin type, severity of the treated condition, 
treatment area, bone proximity, etc.  Set conservative parameters for the first  treatment, and then 
gradually increase during treatment or in subsequent treatments according to the desired impact and treatment  results.  
To perform the treatment, place the tip on the target zone, perpendicular to the skin surface and with full contact [CONTACT_8124].  Emit a pulse by [CONTACT_10394]'s trigger; this will create a tip -shaped 
pattern on the patient's skin that will appear 1 -2 minutes later. Move the applicator to an adjacent spot 
on the skin overlappi[INVESTIGATOR_10373] 10% and emit another pulse . There should be no untreated gaps between the 
pulses.  
Examine the treated area. The immediate responses, indicative of the desired effect, are erythema and edema in the immediate area of the tip -shaped pattern and possibly also around it. The edema usua lly 
appears 1 -2 minutes after pulsing and reaches its peak (of up to moderate edema) within 30 minutes. It 
should be noted that erythema is not easily noticeable –  if at all – in darker skin types. Therefore, the 
edema will be more prominent in these patients. After completing a full pass on the entire treatment area, if untreated patches of skin are apparent, re -treat these patches as per the following procedure:  
i. Wipe the untreated patch of skin with a dry gauze pad.  
ii. Treat the untreated patches of s kin as normally.  
Fine -tuning of the parameters should be done before proceeding to treatment of the entire sub -area 
with the selected parameters. Treatment consists of a single pass over the designated area. The applicator tip should be placed on the skin,  a pulse emitted, then lifted and moved to an adjacent spot 
of the skin. The emitted pulses should create tip -shaped patterns. Leave, no untreated gaps between 
the pattern marks, while also being careful not to overlap the treated zones. The parameters can  be 
modified during subsequent visits, as per the practitioner's discretion.  
Post -Treatment Care  
Post -treatment cooling is not necessary.  In the event of post- treatment discomfort, it is recommended 
to cool the treated area immediately with air cooling.  Cold (not frozen) packs may also be used. Blistered or ulcerated skin can be treated with a prescribed cream. Tiny scabs of less than [ADDRESS_674270] -treatment and may remain for several days. The scabs 
should not be touche d or scratched even if they itch, and should be allowed to shed off naturally. 
Blistered or ulcerated skin can be treated with a prescribed antibiotic ointment or burn treatment cream 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  14 as per physician's discretion.  During the first two days following treatment, care should be taken to 
prevent trauma to the treated site.  Hot baths, massage, etc. should be avoided. The skin should be kept clean to avoid contamination or infection.  Any mechanical or thermal damage to the area must be avoided.  Moisturizer m ay be applied only 24 hours after each treatment, and then should be applied 
regularly throughout the course of the treatment.  Make- up may be applied only 24 hours after each 
treatment if desired, unless an unwanted reaction occurs in the area.  Generally , 24 hours after 
treatment, patients may use regular soaps, but not scrub soaps or exfoliants. The patient should use a 
high -factor sunscreen (at least 30 SPF) and protect the treated area from sunlight for at least one month 
after the treatment.  Tanning of any sort (sun exposure, tanning beds, and artificial sunless tanning 
lotions) is not allowed in the treated areas during the entire course of the treatment.  Tanning after treatment may cause hyperpi[INVESTIGATOR_371].  
Photography  
Photographs will be taken prior to first treatment and throughout the study according to specified time points , utilizing standard scientific equipment.     
The photos should be taken in a private room or area of the clinic under controlled conditions, including 
the distance, angle, b ackground and lighting in order to achieve high -quality sets of photographs.   The 
subject should be placed in the same position each time.  As each photograph is taken, it should be 
viewed to ensure that it is in focus and is similar to its baseline count erpart in all technical aspects, 
including lighting, distance and angle.  
For consistency purposes, the same person should ideally take all study photographs, especially per 
subject.  The digital files should follow a consistent standard naming scheme.  
7.3.4  FOLLOW UP VISITS  
Visit 4 – [ADDRESS_674271] Final Treatment (+/ - 7 days)  
Subjects will return to the clinic [ADDRESS_674272]  Satisfaction questionnaire . 
Photographs of the treated area will be taken as described in section 7.3. 3. The photographs will be sent 
to the b linded independent reviewer for the Global Aesthetic Improvement Scale (GAIS) /Fitzpatrick 
Wrinkle and Elastosis Scale (FWES) assessment .   
Visit 5 – [ADDRESS_674273] Final Treatment (+/ - 7 days)  
Subjects will return to the clinic for a final stud y visit [ADDRESS_674274]  
Satisfaction questionnaire . 
Photographs of the treated area will be taken as described in section 7. 3.3. The photographs will be sent 
to the blinded independent reviewer for GAIS /FWES assessment.   
The termination form will be completed,  and s ubjects will be terminated from the study.  The PI [INVESTIGATOR_519795] 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study participation.  
7.3. 5 EARLY TERMINATION VISIT  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- [ADDRESS_674275] be completed .  
Adverse events and the reason for early termination will be recorded.  
7.3.6  UNSCHEDULED VISIT  
If an unscheduled visit occurs, the reason for the unscheduled visit will be documented. I f the 
unscheduled visit is the result of an adverse event, the event will be recorded on the adverse event CRF.  
7.3.7  SCHEDULE OF E VENTS TABLE  
 
 
 
 
 
7.4 JUSTIFICATION FOR SENSITIVE PROCEDURES  
 This is a non -life-threatening aesthetic treatment  with a low potential for serious adverse events . 
7.5 CONCOMITANT MEDICATIONS, TREATMENTS, AND PROCEDURES  
All concomitant prescription medications taken during study participation will be recorded on the case 
report  forms (CRFs).   For this protocol, a prescription medication is defined as a medication that can be 
prescribed only by a properly authorized/licensed clinician.  Other m edications to be reported in the CRF Procedures  
Screening Visit  
(Day  -7 to - 2 ) 
Baseline/Treatment 1  
(Visit 1, Day 0)  
Treatment 2  
(Visit 2, Week 4 (+/ - 7 days)  
Treatment 3  
(Visit 3, Week 8 (+/ - 7 days)  
Follow -up 1  
(Visit 4, [ADDRESS_674276] -Final 
Treatment +/ - 7 days)  
Follow -up 2  
(Visit 5, [ADDRESS_674277] -Final 
Treatment +/ - 7 days))  
Informed consent  X      
Inclusion/exclusion criteria  X      
Demographics  X      
Medical history  X      
Physical exam  X      
Concomitant medication  X X X X X X 
Urine pregnancy test  X      
Photographs  X X X X X X 
Administer Treatment   X X X   
Adverse event evaluation   X X X X X 
Wong -Baker FACES Pain Scale and 
Tolerability Scale   X X X   
PI [INVESTIGATOR_484518] & short -term response   X X X   
Subject  Satisfaction questionnaire      X X 
Global Aesthetic Improvement Scale   X   X X 
Fitzpatrick Wrinkle and Elastosis Scale   X   X X 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  16 are concomitant over- the-counter medications , non-prescription medications  and herbal/naturopathic 
preparations . 
7.[ADDRESS_674278] degree burn 
or pain beyond narcotics, then the following procedure will be implemented:  
• Immediate triage and treatment of the patient shall be determined by [CONTACT_519806] a nd type of burn identified.  
• The event will be reported to the sponsor study Director within [ADDRESS_674279] be reported on the SAE form.  
• An anonymized  copy of the patient chart and treatment p arameters are to be forwarded to the 
sponsor study Director within 24 hours.   
The sponsor study Director will be responsible for issuing a written report to the company and the EC or 
IRB Chairman no later than 7 days from the event   
Long term follow up and care shall continue at the discretion of the treating physician.  
All patients experiencing a complication of the device will be followed a minimum of 2 years following 
the initial injury.  Longer care and observation will be at the  discretion of the treating physician.   
All minor complications such as appearance or altered sensation, except for pain, can be reported within 30 days of patient complaint.  Both chart and treatment parameters are to be provided to the study 
Director an d shared with the company and EC or IRB chairman.   
8 ASSESSMENT OF SAFETY  
 
8.1 SPECIFICATION OF SAFETY PARAMETERS 
In addition to spontaneous reports of adverse events, subjects will complete a  Wong -Baker FACES Pain 
Scale  and Tolerability Scale and the principal investigator [INVESTIGATOR_519796].  
8.1.1  DEFINITION OF ADVERSE EVENTS (AE)  AND ADVERSE DEVICE EFFECT (ADE)  
Adverse event means any untoward medical occurrence, unintended disease or injury, or untoward 
clinical signs (including  abnormal laboratory findings) in subjects, users or other persons, whether or not 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  17 related to the investigational medical device . This definition includes events related to the 
investigational me dical device or the comparator.  This definition includes events rela ted to the 
procedures involved.  For users or other persons, this definition is restricted to events related to 
investigational medical devices  (ISO [ZIP_CODE]: 2011 ). 
Adverse  device effect means any adverse event related to the use of an investigational medical device . 
This definition includes adverse events resulting from insufficient or inadequate instructions for use , 
deployment, implantation, installation, or operation, or any malfunction of the investigational medical 
device.  This definition includes any event resulting from use error or from intentional misuse of the 
investigational medical device  (ISO [ZIP_CODE]:2011).  
8.1.2  DEFINITION OF SERIOUS ADVERSE EVENTS  (SAE)  
NOTE: The term serious is not synonymous with severity, which may be used to describe the intensity of 
an event experienced by [CONTACT_423]).  An AE that does not meet any of the below criteria will be 
classified as non -serious.  
A serious AE  is any adverse event that:  
• led to death,  
• led to serious deterioration in the health of the subject, that either resulted in  
− a life -threatening illness or injury, or  
− a permanent impairment of a body structure or a body function, or  
− in-patient or prolonged hospi[INVESTIGATOR_059],  or 
− medical or surgical intervention to prevent life -threatening illness or injury or permanent 
impairment to a body structure or a body function,  
• led to fetal distress, fetal death or a congenital abnormality or birth defect  
Planned hospi[INVESTIGATOR_272] a pre-existing condition, or a procedure required by [CONTACT_10396], without serious  
deterioration in health, is not considered a serious adverse event (ISO [ZIP_CODE]:2011) . 
8.1.[ADDRESS_674280] ( SADE) 
This definition  include s any adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event .  Unanticipate d serious adverse device effect ( [LOCATION_003]DE ) is any 
serious adverse device effect which by [CONTACT_5942], incidence, severity or outcome  has not been identified 
in the current version of the risk analysis report .  Anticipated serious adverse device effect (ASADE) is an 
effect which by [CONTACT_10397], incidence, severity or outcome has been identified in the risk analysis report 
(ISO14155:2011).  
8.1.[ADDRESS_674281] to its identity, quality, durability, reliability, safety or 
performance .  Device deficiencies include malfunctions, use e rrors, and inadequate labelling (ISO 
[ZIP_CODE]:2011).  
Any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action had not 
been taken or b) intervention had not been made or c) if circumstances had been less fortunate  is 
subject to  the same reporting requirement of SAEs (MEDDEV 2.7/3 revision 3).  
 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  18 8.2 CLASSIFICATION OF AN ADVERSE EVENT  
 
8.2.1  SEVERITY OF EVENT  
For AEs not included in the protocol defined grading system, the following guidelines will be used to 
describe severity.  
• Mild  – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.  
• Moderate  – Events result in a low level of inconvenience or concern with the therapeutic 
measures.  Moderate events may cause some interference with fun ctioning.  
• Severe  – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.  
8.2.2  RELATIONSHIP TO INVESTIGATIONAL DEVICE  
The cl inician’s assessment of an AE's relationship to the investigational device  is part of the 
documentation process, but it is not a factor in determining what is or is not reported in the study.  If 
there is any doubt as to whether a clinical observation is an AE, the event should be reported.   All AEs 
must have their relationship to investigational device  assessed.  In a clinical trial, the study product must 
always be suspect. To help assess ment , the following guidelines are used.  
• Not Related  – relation  to the device or procedure can be excluded  when:  
− The event is not a known side effect of the product category the device belongs to or of similar 
devices and procedures;  
− the event has no temporal relationship with the use of the  investigational de vice or the 
procedures;  
− the serious event does not follow a known response pattern to the medical device (if the response 
pattern is previously known) and is  biologically implausible  
− the discontinuation of medical device application or the reduction of the  level of 
activation/exposure - when clinically feasible –  and reintroduction of its use (or increase of the 
level of activation/exposure) , do not impact on the serious event;  
− the event involves a body -site or an organ not expected to be affected  by [CONTACT_519807];  
− the serious event can be attributed to another cause (e.g. an underlying  or concurrent illness/ 
clinical condition, an effect of another device,  drug, treatment or other risk factors) . 
• Unlikely: the relationship with the use of the devic e seems not relevant and/or  the event can be 
reasonably explained by [CONTACT_5748], but additional  information may be obtained.  
• Possible : the relationship with the use of the investigational device is weak but  cannot be ruled out 
completely.  Alternative c auses are also possible (e.g. an  underlying or concurrent illness/ clinical 
condition or/and an effect of another device, drug or treatment).  Cases were relatedness cannot be 
assessed or no  information has been obtained should also be classified as possible.  
• Probable : the relationship with the use of the investigational device seems  relevant and/or the 
event cannot reasonably be explained  by [CONTACT_5748], but  additional information may be 
obtained.  
• Causal relationship : the serious event is associate d with the investigational device or with 
procedures beyond reasonable doubt when:  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  19 − the event is a known side effect of the product category the device belongs to or of similar 
devices and procedures;  
− the event has a temporal relationship with investigation al device use/application or procedures;  
− the event involves a body -site or organ that the investigational device or procedures are applied 
to or the investigational device or procedures have an effect on;  
− the serious event follows a known response pattern to the medical  device (if the response 
pattern is previously known);  
− the discontinuation of medical device application (or reduction of the  level of 
activation/exposure) and reintroduction of its use (or increase of the  level of 
activation/exposure), impac t on the serious event (when  clinically feasible);  
−  other possible causes (e.g. an underlying or concurrent illness/ clinical condition or/and an 
effect of another device, drug or treatment) have  been adequately ruled out;  
− harm to the subject is due to err or in use;  
8.2.3  EXPECTEDNESS  
Expected  (anticipated)  adverse reactions are AEs that are common and known to occur for the 
investigational device being  studied.   Expected  adverse events in this study include d iscomfort or 
significant pain post -treatment, e xcessive skin redness (erythema) and/or swelling (edema) , in-grown 
hairs , damage to natural skin texture (crust, blister, burn) , change of pi[INVESTIGATOR_371] (hyper - and hypo -
pi[INVESTIGATOR_371]) , scarring . Treatment of hair- bearing areas in males may result in some damage to the 
follicles and subsequent loss of hair.   
An AE or suspected adverse reaction is considered "unexpected"  (unanticipated) if it is not known to 
occur for the investigational device being studied and at the specificity or severity that has been 
observed  (AE not described into the Clinical protocol or User Manual).  
8.3 TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor.  All AEs 
including local and systemic reactions not meetin g the criteria for SAEs will be captured on the 
appropriate CRF.  Information to be collected includes event description, time of onset, clinician’s 
assessment of severity, relationship to investigational device and study procedures (assessed only by 
[CONTACT_519808] a diagnosis), and time of resolution/stabilization of the 
event.  All AEs occurring while on study must be documented appropriately regardless of relationship. 
All AEs will be followed to adequate resolution.  
Any me dical condition that is present at the time that the participant is screened will be considered as 
baseline and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event 
at each level of severity to be performed.  AEs characterized as intermittent require documentation of 
onset and duration of each epi[INVESTIGATOR_1865].  
The PI [INVESTIGATOR_519797].  At each study visit, the investigator will inquire study subjects about the occurrence of 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  20 AE/SAEs since the last visit. All adverse events need to be followed un til resolution or until study end, 
whichever occurs first . 
8.4 REPORTING PROCEDURES  
 
8.4.1  ADVERSE EVENT REPORTING  
All AEs will be recorded on the appropriate CRF and will include information about the start and stop 
dates, severity and relatedness.  There should be an attempt to report a “diagnosis” rather than the 
individual signs, symptoms and abnormal laboratory values associated with the diagnosis. However, a diagnosis should be reported only if, in the Investigator’s judgment, it is relatively ce rtain (i.e., definite 
or possible). Otherwise individual signs, symptoms and abnormal laboratory values should be reported as distinct  adverse events.  
8.4.[ADDRESS_674282] be reported to the  sponsor’s 
clinical research department immediately or within 24 hours  by [CONTACT_10399] (see contact 
[CONTACT_2212]).  
Name: [CONTACT_484543], Clinical Research Manager  
Phone: 888 -907-0115 ext. 127 
Email: [EMAIL_9329] m 
Address: [ADDRESS_674283], Toronto, Ontario, Canada, M2J 1R4  
A written report prepared by [CONTACT_079] (or designate ) must follow within seven working 
days to the clinical monitor and should include a full description of the event a nd sequence.  
The study investigator shall complete a Serious Adverse Event / Serious Adverse Device Effect Form and 
submit to the study sponsor as soon as possible, but in no event later than [ADDRESS_674284].  
In accordance with the requirements of Directive 93/42/EEC, and with MEDDEV 2.7/3, the following events are considered reportable events:  
1. any SAE (whether or not study  procedure or device related),  
2. any Investigational Medical Device Deficiency that might have led to a SAE if a) suitable action had not been taken or b) intervention had not been made or c) if circumstances had been les s 
fortunate,  
3. new findings/updates in relation to already reported events.  
 The sponsor will report the above -mentioned  events to the Competent Authorities of all countries 
where the study is being conducted, within the following timelines:  
− Any SAE which in dicates an imminent risk of death, serious injury, or serious illness AND that 
requires prompt remedial action for other patients/subjects, users or other persons or a new finding to it: immediately, but not later than 2 calendar days after awareness by [CONTACT_519809] a 
new reportable event or of new information in relation with an already reported event.  
− Any other reportable event or a new finding / update to it: immediately, but not later than 7 calendar days following the date of awareness by [CONTACT_41493].  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  21  
Reporting of the events listed above (under bullets 1 -3) to the ECs of  the participating sites and to the 
other investigators will be performed according to country  and/or site-specific  requirements.  
 
8.4. [ADDRESS_674285] or Partner Pregnancy Outcome form within  10 business days.  
8.5 STUDY HALTING RULES  
The study may be halted at any time by [CONTACT_456], the EC / IRB, Competent Authorities due  to safety 
concerns.  Examples of findings that might trigger a safety review are the number of SAEs overall, the 
number of occurrences of a particular type of SAE, severe AEs/reactions, or increased frequency of events.   If the study is halted, the sponsor will immediately notify  all investigational sites, the EC / IRB(s), 
the Competent Authorities of all countries where the study is being conducted.  
8.6 SAFETY OVERSIGHT  
Independent oversight is an important component to ensure  human subjects' protection.  Safety 
oversight will be under the direction of the sponsor and a medical monitor.  
8.7 TRAINING REQUIREMENTS  
Prior to patients’ enrollment, the Sponsor will provide training relevant and pertinent to the involvement of personnel conducting study activities. Training for investigators and staff will include study -specific protocol and CRF completion training by [CONTACT_3433] e sponsor or designate and on -site training on 
the use of the investigational device by [CONTACT_456].  Evidence of training will be documented during the 
site initiation visit and by [CONTACT_10403] a device training certificate.  
[ADDRESS_674286] of the trial is in compliance with the currently appro ved protocol/amendment(s), with GCP, and with 
applicable regulatory requirement(s).  
• Monitoring for this study will be performed by [CONTACT_10404] . 
• On-site monitoring will occur within [ADDRESS_674287] and will occur at a 
frequenc y described in the Monitoring Plan.  
• Variables to be monitored will be described in the Monitoring Plan.  
• The Study Director or designate will be provided copi[INVESTIGATOR_10376] 15 business 
days of visit.  
 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  22 10.1 STATISTICAL AND ANALYTICAL PLANS  
The Statistical and Analytical Plans (SAP) may be revised during the study to accommodate Clinical Trial 
Protocol Amendments and to make changes to adapt to unexpected issues in study execution and data 
that affect planned analyses. If revised, a formal Sta tistical and Analytical Plans (SAP) will be completed 
and issued  prior to database lock and unblinding of the study data.   
10.2 STATISTICAL HYPOTHESES  
The null and alternative hypotheses for the study’s primary, key secondary and safety endpoints are;  
• Primary Efficacy Endpoint:  
Null Hypothesis (H o: µd = µpost – µpre = 0) – There is no improvement in acne scarring or wrinkles  at 
6-week and [ADDRESS_674288]- treatment compared to baseline as assessed by [CONTACT_484534] (GAIS) or Fitzpatrick Wrinkle and Elastosis Scale (FWES).  
 
Alternative Hypothesis (H a: µd = µpost – µpre ≠ 0)  – There is an Improvement in  acne scarring  or 
wrinkles at 6-week and [ADDRESS_674289]- treatment compared to baseline as assessed by [CONTACT_519810] (GAIS)  
or Fitzpatrick Wrinkle and Elastosis Scale (FWES) . The efficacy endpoint improvement is defined 
as a score of >  1.25 on the Global Aesthetic Improvement Scale (GAIS) /Fitzpatrick Wrinkle and 
Elastosis Scale (FWES) . This is  the expected mean difference  in GAIS /FWES score at [ADDRESS_674290] -treatment assessment compared to baseline.   
 
• Secondary Efficacy Endpoint(s):  
The following Null Hypotheses (H o: µd = µpost – µpre = 0) - There is no improvement in subjects’ 
assessment of satisfaction with the treatment using a Patient Satisfaction Questionnaire at [ADDRESS_674291]- treatment.  
 The following Alternative Hypotheses (H
a: µd = µpost – µpre  ≠ 0) - There is an improve ment in 
subjects’ assessment of satisfaction with the treatment using a Patient Satisfaction Questionnaire at [ADDRESS_674292]- treatment.  
 
• Safety Endpoint : 
Null Hypothesis (H
o: µd = µpost – µpre = 0) – There is no difference in subjects’ Wong -Baker FACES 
Pain Scale  and Tolerability Scale experienced at Visit 3 treatment compared to that which was 
experienced at baseline treatment (Visit 1).  
 
Alternative Hypothesis (H a: µd = µpost – µpre ≠ 0)  – There is a difference in subjects’ 
discomfort/pain Wong- Baker FACES Pain Scale  score and Tolerability Scale experienced at Visit 3 
treatment compared to that which was experienced at baseline treatment (Visit 1) . 
 
10.3 ANALYSIS DATASETS  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  23 Modified Intent ion-to-Treat Analysis Dataset will be used; Efficacy and safety analyses will be carried out 
on all subjects who received at least one treatment of Venus Viva™ fractional RF device  and for whom at 
least one valid post -baseline efficacy and safety evaluatio n were obtained.  
10.4 DESCRIPTION OF STATISTICAL METHODS  
 
10.4.1 GENERAL APPROACH  
This is prospective, single centre, evaluator -blind study of the safety and performance of fractional 
radiofrequency (RF) for the treatment and reduction of acne scarring or wrinkles .  
All summary tables for quantitative parameters will display mean, standard deviation, median, range 
(minimum and maximum), percentages as well as number of missing data (if relevant). All summary tables 
for qualitative parameters will display counts, percentages and number of missing data if relevant. Baseline data are defined as the last measurement , photograph or assessment performed before the first 
treatment on Visit 1 .  
All statistical tests will be one-sided  (1-tailed) . The level of statistical significance for effectiveness analyses 
is 5% (α = 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed -Ranks 
Test for Matched Pairs will be used to compare the evaluations at the baseline and post tr eatment 
sessions. This test will enable us to accept or reject the null hypotheses. Rejection of null hypotheses will establish that:  
• The one-sided 95% confidence interval for the difference between the means excludes zero.  
• The two means are statistically significantly different at the 5% level ( P < 0.05) one-sided.  
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t -test 
will be used to determine the efficacy of the treatment.  
In other to accommodate imbal ances of some baseline GAIS/FWES  score s, covariate adjustment analysis 
may be performed in SAP to estimate adjusted treatment effects for the primary endpoint analysis.  
The assumption for the statistical test is that the paired differences of baseline and post treatment data are normally distributed  
10.4.2 ANALYSIS OF THE PRIMARY EFFICACY ENDPOINT(S)  
The following will be considered for the analysis primary endpoint:  
Summary table for differences of baseline compared to  6-week and baseline compared to  12-week post -
treatment  GAIS/FWES  score s will be displayed as mean difference, standard deviation and standard error.  
The Global Aesthetic Improvement Scale (GAIS) Fitzpatrick Wrinkle and Elastosis Scale (FWES) are   ordinal 
scale tools that can be used to assess  reduction of acne scarring and wrinkles.  
 
Bar, pie  charts or graphs indicating scores, percentages or proportions of subjects with Global Aesthetic 
Improvement Scale (GAIS)/  Fitzpatrick Wrinkle and Elastosis Scale (FWES).  
 
All statistical tests will be one -sided. The level of statistical significance for effectiveness analyses is 5% (α 
= 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed -Ranks Test 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- [ADDRESS_674293] treatment assessments. Analysis of Covariance (ANCOVA) may also be used 
where appropriate. Since the primary endpoint is based on achieving a fixed scale point on the 
GAIS/FWES, covariate adjustment analysis may be performed in SAP to estimate adjusted treatment 
effects for the primary endpoint analysis  in covariate adjustment analysis may be performed in SAP to 
estimate adjusted treatment effects for the primary endpoint analysis.   
The Paired t -test and/or Wilcoxon Signed -Ranks Test for Matched Pairs will enable us to accept or reject 
the null hypotheses. Rejection of null hypotheses will establish that:  
• The one-sided 95% confidence interval for the difference between the means excludes zero.  
• The two means are statistically significantly different at the 5% level ( P < 0.05) one-sided.  
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t -test 
will be used to test expected pr imary endpoint; that is alternative hypothesis that Ha > 0.75. This will be 
used to determine if the study meets  the primary endpoint ; GAIS/FWES  score of > 0.75.  
GAIS/FWES scores of all subjects who received at least one treatment of Venus Viva™ fractional RF device and for whom at least one valid post -baseline GAIS/FWES assessment were obtained will be 
analysed for the primary endpoint. Multiple imputation  method or modelling of available data may be used for missing data as appropriate.  
10.4.3 ANALYSIS OF THE SECONDARY ENDPOINT(S)  
For the analysis of secondary endpoints, the following analysis will be considered:  
Summary tables for differences of baseline compared to  6-week and baseline compared to  12-week post-
treatment  of subjects’ assessment of satisfaction with the treatment using a Patient Satisfaction 
Questionnaire  will be displayed as mean difference, standard deviation and standard error.  The point 
level for each of these ordinal scale assessment tools will be put into consideration wher e applicable.  
 
Bar charts, pie chart, graphs or any other descriptive statistical displays indicating scores, percentages or proportions of Subjects’ assessment of satisfaction with the treatment using a Patient Satisfaction 
Questionnaire  will be used to analyse efficacy.  
 All statistical tests that will be one -sided. The level of statistical significance for effectiveness analyses is 
5% (α = 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed -Ranks 
Test for Matched Pairs will be used to compare the evaluations score differences of baseline compared to  
6-week and baseline compared to  12-week  post treatment assessment. Analysis of Covariance (ANCOVA) 
may also be used where appropriate.  
Subjects’ asses sment of satisfaction with the treatment using a Patient Satisfaction Questionnaire  of all 
subjects who received at least one treatment of Venus Viva™ fractional RF device  and for whom at least 
one valid post -baseline assessment were obtained will be analy sed for these secondary endpoints. 
Multiple imputation  method or modelling of available data may be used for missing data as appropriate.  
10.4.4 SAFETY ANALYSES  
The safety analysis will be done by [CONTACT_10407]  (AE), subjects ’ 
complete d Wong- Baker FACES Pain Scale  and Tolerability Scale  as well as analysis of immediate and short 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  25 term response  reports by [CONTACT_458] [INVESTIGATOR_10377]/her observation/examination of the treated 
area. Appropriate Medical Dictionary f or Regulatory Activities (MedDRA ) code will be used to describe all 
spontaneous ly report ed or other study related  adverse events . 
Summaries of spontaneous ly report ed or other study related  adverse events  will be presented as : 
o Number (%) of subject s with any AE,  
o Number (%) of subject s with any  serious adverse events  (SAE), 
o Number (%) of subject s permanently wit hdrawn from treatment due to AE  
Summaries of analysis of immediate and short term response  reports by [CONTACT_458]  
[INVESTIGATOR_10378] a  bar or pie chart as;  
o the overall frequency of subject s with each event (pain during treatment, hemorrhage, burn, 
erythema, edema, purpura)  
o Frequency of subject s with specific severity/ intensity for each event  using a 5 points scale: 
1=none; 2=trace; 3=moderate; 4=marked; 5=severe  
o The overall percentage  or proportion o f subject observed with marked or severe intensity of any 
event will be calculated and compared to those with none, trace or moderate severity/intensity 
with the aid of a bar or pie chart.  
The following will be considered for the analysis of Wong -Baker FACES Pain Scale  scores   safety data:  
Summary table for differences of baseline and Visit [ADDRESS_674294] error.  The Wong- Baker FACES Pain 
Scale  is a 10 point visu al scale tool for assessing pain.  
 
Bar, pie  charts or graphs indicating scores, percentages or proportions of subjects with Visi t 3 treatment 
and baseline  (Visit 1) Wong -Baker FACES Pain Scale  scores  difference and Tolerability Scale will be used 
to analyse subjects’ tolerability of this treatment . 
 All statistical tests will be one -sided. The level of statistical significance for effectiveness analyses is 5% (α 
= 0.05) for all tests of differences. Where appropriate, Paired t -test and/or Wilcoxon Signed -Ranks Test 
for Matched Pairs will be used t o compare the difference  between baseline and Visit [ADDRESS_674295] and/or Wilcoxon Signed -Ranks Test for Matched Pairs will enable us to accept or reject 
the null hypotheses. Rejection of null hypotheses will establish that:  
• The one-sided 95% confidence interval for the difference between th e means excludes zero.  
• The two means are statistically significantly different at the 5% level ( P < 0.05) one-sided.  
Upon rejection of null hypotheses, further statistical test tools such as Confidence Interval and/or t -test 
will be used to test expected safety endpoint; that is alternative hypothesis,  Ha < 1.  
10.4.5 ADHERENCE AND RETENTION ANALYSES  
Adherence to the protocol will be assessed  by [CONTACT_10408] (%) subjects’ data for each endpoint 
assessment that is not provided in subjects Case Report Forms. This will be further analysed as per 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  26 frequency of each endpoint data that is not available due to l oss to follow -up, discontinuat ion of the 
intervention  or any other reason . 
 
10.4.6  BASELINE DESCRIPTIVE STATISTICS  
Subjects baseline scores of all endpoints (GAIS, FWES, Patient Satisfaction Questionnaire, Wong- Baker 
FACES Pain Scale  and Tolerability Scale) will be compared using  desc riptive statistics  such as mean score, 
standard deviation, standard error, range and graphical presentations.   
10.4.7 PLANNED INTERIM ANALYSES  
N/A - There will be no interim analysis during this study.  
 
[IP_ADDRESS]  SAFETY REVIEW  
There will be no interim analysis during this study . However, t his study may be temporarily suspended or 
prematurely terminated if there is sufficient reasonable cause  as per section 5.5 and 8.5.   
[IP_ADDRESS]  EFFICACY REVIEW  
There will be no interim analysis during this study . However, t his study may be temporarily suspended 
or prematurely terminated if there is sufficient reasonable cause  as per section 5.5 and 8.5.   
10.4.8  ADDITIONAL SUB -GROUP ANALYSES 
Not Applicable -  Primary or secondary endpoint will not be analyzed based o n age, sex, race/ethnicity or 
other demographic characteristic(s).  
10.4.9 MULTIPLE COMPARISON/MULTIPLICITY  
Not Applicable   
10.4.10  TABULATION OF INDIVIDUAL RESPONSE DATA  
Individual participant data will be listed by [CONTACT_484535] t he study report . 
10.4.11  EXPLORATORY ANALYSES  
Not Applicable   
10.5 SAMPLE SIZE  
The primary endpoints outcome measures w as used to calculate the study sample size.  
Sample size calculation using primary endpoint outcome measure;  
• Null and alternate hypotheses:  
o Null Hypothesis (H o: µd = µpost – µpre = 0) – There is no improvement in acne scarring or 
wrinkles at [ADDRESS_674296]- treatment compared to baseline as assessed by 
[CONTACT_519811] 1.0 
Protocol #VI0919  19-June- 2019  
  27 blinded evaluators by [CONTACT_519812] (GAIS)/Fitzpatrick Wrinkle and Elas tosis Scale.  
 
o Alternative Hypothesis (H a: µd = µpost – µpre ≠ 0)  – There is an Improvement in  acne scarring 
or wrinkles at [ADDRESS_674297] -treatment compared to baseline as assessed by 
[CONTACT_519813] l Aesthetic Improvement 
Scale (GAIS)/ Fitzpatrick Wrinkle and Elastosis Scale (FWES). The efficacy endpoint 
improvement is defined as a score  of > 1.25  on the Global Aesthetic Improvement Scale 
(GAIS)/Fitzpatrick Wrinkle and Elastosis Scale (FWES). This is  the e xpected mean 
difference  in GAIS/FWES score at 6-week and [ADDRESS_674298]- treatment assessment 
compared to baseline.  
• In view of the nature of this study in regard to treatment and follow -up duration , we make 
provision for  20% study drop out, withdrawal or loss to follow -up. 
• 1-Tailed Sample Size calculation formula for Matched Samples  for GAIS scores was used in the 
table below:  
 
(1-β), Power  0.8 
α, Level of Significance  0.05  
μd, mean difference; this is the smallest possible change 
expected under H a 1.[ADDRESS_674299] Deviation of the difference scores (GAIS 
range ÷ 4) = [10 ÷ 4]  2.5 
Z1-α/2 1.645  
Z1-β, (for 90%)  0.84  
Estimated Sample Size   25 
Estimated Sample Size + 20% drop out  30 
Conclusion: The estimated sample size for treatment site and the additional 20% provision for drop out 
(30 treatment sites ) obtained from the primary endpoint outcome measure calculation will be us ed for 
this study.   15 subjects will undergo treatment on 2 different sites; one on each side of the face that will 
be assessed independently as two separate sites.  
10.6 MEASURES TO MINIMIZE BIAS  
 
10.6.1  ENROLLMENT/ RANDOMIZATION/ MASKING PROCEDURES  
At screening, once a subject has signed the informed consent, and inclusion/exclusion criteria has been 
met, a subject number will be assigned. The subject number will consist of a two -digit code corresponding 
to the site and a two digit subject code in nu merical sequence. (Example: 10 -05 corresponds to site #10, 
subject #5.)  
10.6.[ADDRESS_674300] s will receive treatment .   
10.6.3  BREAKING THE STUDY BLIND/ PARTICIPANT  CODE  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  28 N/A - All subject s will receive treatment . 
11 SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS  
Each participating site will maintain appropriate medical and research records for this trial, in 
compliance with ISO [ZIP_CODE]:2011 , and regulatory and institutional requirements for the protection of 
confi dentiality of participants. Each site will permit authorized representatives of the study sponsor , 
ethic s committee and/or regulatory agencies to examine (and when permitted by [CONTACT_1289], to 
copy) clinical records for the purposes of quality assurance  reviews, audits, and evaluation of the study 
safety, progress, and data validity.  
Source data are all information, original records of clinical findings, observations, or other activities in a 
clinical trial necessary for the reconstruction and evaluatio n of the trial. Examples of these original 
documents and data records include, but are not limited to, hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, participants' memory aids or evaluation checklists, pharmacy dispensing 
record s, recorded audio tapes of counseling sessions, recorded data from automated instruments, 
copi[INVESTIGATOR_10379], microfiches, 
photographic negatives  (where  applicable) , microfilm or magnetic me dia, x -rays, and participant files 
and records kept at the pharmacy, at the laboratories, and medico -technical departments involved in 
the clinical trial.  
It is acceptable to use CRFs as source documents.  The following CRFs collected on no carbon require d 
(NCR) paper will be source documents:  
• Subject self -reported Wong -Baker FACES Pain Scale  and Tolerability  Scale, GAIS /FWES  and 
Subject Satisfaction questionnaire  
The remainder of the data  collected from other sources.  
It is no t acceptable for the CRF to  be the only record of a subject’s  participation in the study. This is to 
ensure that anyone who would access the patient medical record has adequate knowledge that the 
patient is participating in a clinical trial.  
12 QUALITY ASSU RANCE AND QUALITY CONTROL  
Prior to any independent use of the Venus Viva ™ device, study personnel, will receive proper training 
from the sponsor. Site personnel will be trained on the use of the device prior to study initiation at the 
site.  Additional  training requirements will be discussed during study initiation and will include site 
responsibilities, and study documentation.  In addition, the sponsor will provide protocol specific training 
for the site. The site will document which individu al has been assigned to a specific task and will ensure 
that appropriate training has occurred for that task.  
Regular monitoring and an independent audit, if conducted, must be performed according t o ISO 
[ZIP_CODE]:2011. See also Section 9, Clinical Monitoring.  
Quality control ( QC) procedures will be implemented beginning with the data entry system and data QC 
checks that will be run on the database will be generated.  Any missing data or data anomalies will be 
communicated to the site(s) for clarification/resolution.  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  29 Monitors will verify that the clinical trial is conducted,  and data are generated, documented (recorded), 
and reported in compliance with the protocol, GCP, and the applicable regulatory requirements.  
The investigational site will provide direct acc ess to all trial related sites, source data/documents, and 
reports for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_10412].  
13 ETHICS/PROTECTION OF HUMAN SUBJECTS  
 
13.[ADDRESS_674301] version of the 
Declaration of Helsinki (2013), ISO [ZIP_CODE]:2011 (Clinical investigation of medical devices for human 
subjects - Good clinical practice) , FDA and any o ther applicable country’s  ethical policy statement, 
whichever provides the higher level of protection to human subjects.  
13.2 ETHICS COMMITTEE AND COMPETENT AUTHORITIES   
The protocol, informed consent form(s), recruitment materials, and all participant mat erials will be 
submitted to the EC  / IRB  for review and approval. Approval of both the protocol and the consent form 
must be obtained before any participant is enrolled. Any amendment to the protocol will require review 
and approval by [CONTACT_1383] / IRB before the changes are implemented to the study. All changes to the 
consent form will be EC  / IRB approved; a determination will be made by [CONTACT_10413] -consented.  
13.3 INFORMED CONSENT PROCESS  
 
13.3.1  CONSENT/ASSENT AND O THER INFORMATIONAL DOCUMENTS PROVIDED TO 
PARTICIPANT S 
Informed consent is required for all subjects in a study.  In obtaining and documenting informed 
consent, the investigator should comply with applicable regulatory requirements and should adhere to ISO [ZIP_CODE]:[ADDRESS_674302] version of the Declaration of Helsinki (2013) .  Prior to th e beginning of 
a trial, the investigator should have the EC / IRB's written approval for the protocol and the written 
informed consent  forms(s) and any other written information to be provided to the participants.  
Consent forms describing in detail the investigational medical device , study procedures, and risks are 
given to the participant and written documentation of informed consent is required prior to starting 
intervention  with  investigational medical device . 
13.3.2  CONSENT PROCEDURES AND DOCUMENTATION  
Informed consent is a process that is initiated prior to the ind ividual’s agreeing to participate in the 
study and continues throughout the individual’s study participation. Extensive discussion of risks and possible benefits of participation will be provided to the participants and their families.   Consent forms 
will be EC or IRB approved and the participant will be asked to read and review the document. The 
investigator will explain the research study to the participant and answer any questions that may arise. All participants will receive a verbal explanation in term s suited to their comprehension of the purposes, 
procedures, potential risks of the study and their rights as research participants.   Participants will have 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- [ADDRESS_674303] by [CONTACT_3486], their staff, and the 
sponsor(s) and their agents . This confidentiality is extended to cover testing of biological samples in 
addition to the clinical information relating to participants. Therefore, the study protocol, 
documentation, data, a nd all other information generated will be held in strict confidence. No 
information concerning the study or the data will be released to any unauthorized third party without prior written approval of the sponsor.  
The study monitor, other authorized repres entatives of the sponsor, representatives of the EC / IRB and  
Competent Authorities or device  company supplying study product may inspect all documents and 
records required to be maintained by [CONTACT_093], including but not limited to, medical records  
(office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The clinical study site 
will permit access to such records.  
The study participant’s contact [CONTACT_21225]. At the end of the study, all records will continue to be kept in a secure location for as 
long a period as dictated by [CONTACT_456],  and any applicable regulations  (refer to section 14.2 STUDY 
RECORDS RETENTION ). 
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will 
be transmitted to and stored at the sponsor’s office . This will not include the participant’s contact [CONTACT_10415]. Rather, individual participants and their r esearch data will be identified by a 
unique study identification number. The study data entry and study management systems used by 
[CONTACT_100977]’s research staff will be secured and password protected.  At the end of the 
study, all study da tabases will be de -identified and archived by  [CONTACT_456] . 
13.4.[ADDRESS_674304] KEEPI[INVESTIGATOR_1645]  
 
14.1 DATA COLLECTION AND MANAGEMENT RESPONSIBILITIES  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- 2019  
  31 Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site 
Principal Investigator.  The investigator is responsible for ensuring the accuracy, completeness, legibility, 
and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data.  Black ink is required to en sure clarity of reproduced copi[INVESTIGATOR_014]. When making changes or 
corrections, cross out the original entry with a single line, and initial and date the change.  DO NOT 
ERASE, OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Copi[INVESTIGATOR_10380].   Data reported in the CRF derived from source documents 
should be consistent with the source documents or the discrepancies should be exp lained and captured 
in a progress note and maintained in the participant’s official study record.   Self-reported subject data  
and investigator CRF reported data recorded on the copy CRF page is permitted.  The original form will 
be collected by [CONTACT_484539].  
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data from paper CRFs will be entered directly onto paper CRFs from the source documents 
and will be c ollected by [CONTACT_4530].  
14.2 STUDY RECORDS RETENTION  
Study documents , including copi[INVESTIGATOR_10381], signed informed consent forms, photographs  
(where  applicable) , laboratory results, medical records , data clarification forms  and regulatory 
documents,  should be retained for a minimum period of [ADDRESS_674305] udy related materials .  No records will be destroyed without the 
written consent of the sponsor, if applicable.  It is the responsibility of the sponsor to inform the 
investigator when these documents no longer need to be retained.  
14.3 PROTOCOL DEVIATIONS   
A protocol deviation is any instance(s) of failure to follow, intentionally or unintentionally, the 
requirements of the Clinical Investigation Plan.  Applicable definition follow:  
− Major deviation: CIP deviations that can have affected the rights, safety o r well- being of the subject 
or the scientific integrity of the clinical investigation.  
− Minor deviation: CIP deviations that do NOT have affected the rights, safety or well- being of the 
subject or the scientific integrity of the clinical investigation.  
The noncompliance may be either on the part of the participant, the investigator, or the study site staff.  
As a result of deviations, corrective actions are to be developed by [CONTACT_3483].  
These practices are consistent with ISO [ZIP_CODE]:20 11: 
• 4.5 Compliance with Protocol, sections 4.5.1, 4.5.2, and 4.5.3  
• 5.1 Quality Assurance and Quality Control, section 5.1.1  
• 5.20 Noncompliance, sections 5.20.1, and 5.20.2.  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- [ADDRESS_674306] been met:  
a. The Investigator, the Sponsor and Statistician have approved the protocol amendment and  
b. The responsible EC and Competent Authority has reviewed an d approved the protocol change.  
Under emergency circumstances, deviations from the CIP to protect the rights, safety and well -being of 
human subjects may proce ed without prior approval of the sponsor and the EC.  Such deviations shall be 
documented and reported to the sponsor and the EC as soon as possible.  
A corrective action will be taken: documenting the deviation (source document, log, CRF as relevant) including its reasons of occurrence and corrective actions to be taken to further avoid reoccurrence of it 
and properly reporting. The investigator as well as site personnel will be trained in order to avoid any major protocol deviation in the future.  
Failure to comply with this clinical investigation plan and/or EC, Competent Authorities, any local 
requirement will result in corrective actions and could result in the removal of the investigator from the study.  
It is the responsibility of the site to use contin uous vigilance to identify and report deviations  promptly 
to study sponsor and to EC (if required by [CONTACT_1295] ).  All deviations must be addressed in study 
source documents.  The site PI/study staff is responsible for knowing and adhering to their E C 
requirements .  
14.4 PUBLICATION AND DATA SHARING POLICY  
The International Committee of Medical Journal Editors (ICMJE) member journals have adopted a clinical trials registration policy as a condition for publication. The ICMJE defines a clinical trial as any research project that prospectively assigns human subjects to intervention or concurrent comparison or control groups to study the cause -and-effect relationship between a medical intervention and a health 
outcome. Medical interventions include drugs,  surgical procedures, devices, behavioral treatments, 
process -of-care changes, and the like.  Health outcomes include any biomedical or health -related 
measures obtained in patients or participants and adverse events. The ICMJE policy, and the  Section [ADDRESS_674307] of 2007, requires that all clinical trials be 
registered in a public trials registry such as ClinicalTrials.gov, which is sponsored by [CONTACT_1055]. Other biomedical journals are conside ring adopting similar policies.  The Decla ration of 
Helsinki current revision (2013) states that every research study involving human subjects must be registered in a publicly accessible database before recruitment of the first subject (sec.35).  
The sponsor or its designee  will register the
 VI0919 study into a publicly accessible database .  All data 
generated from this study are the property of Venus Concept Ltd and shall be held in strict confidence 
along with all information furnished by [CONTACT_484540] . 
Independent analysis and/or publication of these data by [CONTACT_10420]/her staff are not permitted without prior written consent of Venus Concept Ltd.   Written permission to the 
Investigator will be contingent on the revi ew by [CONTACT_484541]. In all cases, the parties agree to submit all manuscripts or abstracts to all other parties at 
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- [ADDRESS_674308].  
17  LITERATURE REFERENCES  
1. O'Daniel TG. Multimodal management of atrophic acne scarring in the aging face. Aesthetic Plast 
Surg. 2011; 35(6):1143 -50. 
2. Simmons B, Griffith R, Falto -Aizpurua L, Nouri K .  Use of radiofrequency in cosmetic dermatology: 
focus on nonablative treatment of acne scars. Clinical, Cosmetic and Investigational Dermatology. 
2014:7 335— 339 
3. Alster TS, Lupton JR. Nonablative cutaneous remodeling using radiofrequency devices . Clin 
Dermatol. 2007; 25:487 -491.  
4. Alexiades -Armenakas M, Dover JS, Arndt KA. Unipolar versus bipolar radiofrequency treatment of 
rhytides and laxity using a mobile painless delivery method. Lasers Surg Med. 2008;40(7):446 -453 
5. De Felipe I, D el Cueto SR, Pérez E, Redondo P. Adverse reactions after nonablative radiofrequency: 
follow -up of 290 patients. J Cosmet Dermatol. 2007;6(3):163- 166.  
6. Omi T, Sato S, Kaminaka C, Yamamoto Y, Kawana S, et al. (2014) A Histological Study on the 
Treatment of Ac ne Scars with Fractional Radiofrequency: Preliminary Findings. J Clin Exp Dermatol 
Res 5:203 
7. E. Forbat & F. Al -Niaimi (2016)  Fractional radiofrequency treatment in acne scars: Systematic 
review of current evidence,  Journal of Cosmetic and Laser Therapy, 18:8,  442-447 
  
Clinical Evaluation of Fractional Radiofrequency for the Treatment and Reduction of Acne Scars and Wrinkles  Version 1.0 
Protocol #VI0919  19-June- [ADDRESS_674309]  
ISO [ZIP_CODE]:2011  International Organization for Standardization Good Clinical Practices for Clinical 
Investigations of Medical Devices  
MedDRA  Medical Dictionary for Regulatory Activities  
PI [INVESTIGATOR_519798]  
 